Browsing Radiotherapy and Imaging by author "Harrington, Kevin"
Now showing items 101-120 of 158
-
PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.
Dillon, MT; Boylan, Z; Smith, D; Guevara, J; Mohammed, K; et al. (ELSEVIER IRELAND LTD, 2018-08-01)PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and ... -
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Forster, MD; Dillon, MT; Kocsis, J; Remenár, É; Pajkos, G; et al. (ELSEVIER SCI LTD, 2019-12-01)BACKGROUND: The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in recurrent and/or metastatic (R/M) squamous cell carcinoma ... -
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.
Dillon, MT; Grove, L; Newbold, KL; Shaw, H; Brown, NF; et al. (AMER ASSOC CANCER RESEARCH, 2019-01-15)PURPOSE: Patritumab plus cetuximab with platinum as first-line therapy for patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) was evaluated for safety and to determine the ... -
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Smith, HG; Mansfield, D; Roulstone, V; Kyula-Currie, JN; McLaughlin, M; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: The prevention and treatment of metastatic sarcoma are areas of significant unmet need. Immune checkpoint inhibitor monotherapy has shown little activity in sarcoma and there is great interest in identifying novel ... -
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness, B; Harrington, KJ; Greil, R; Soulières, D; Tahara, M; et al. (ELSEVIER SCIENCE INC, 2019-11-23)BACKGROUND: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. METHODS: KEYNOTE-048 was a randomised, phase ... -
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
Machiels, J-P; Tao, Y; Burtness, B; Tahara, M; Licitra, L; et al. (FUTURE MEDICINE LTD, 2020-06-03)Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with ... -
Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.
Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; et al. (2018-04) -
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen, EEW; Soulières, D; Le Tourneau, C; Dinis, J; Licitra, L; et al. (ELSEVIER SCIENCE INC, 2019-01-12)BACKGROUND: There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. ... -
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
Annels, NE; Mansfield, D; Arif, M; Ballesteros-Merino, C; Simpson, GR; et al. (AMER ASSOC CANCER RESEARCH, 2019-10-01)PURPOSE: The CANON [CAVATAK in NON-muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1-targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. PATIENTS AND METHODS: ... -
Plaque Neovascularization Is Increased in Human Carotid Atherosclerosis Related to Prior Neck Radiotherapy A Contrast-Enhanced Ultrasound Study
Shah, BN; Gujral, DM; Chahal, NS; Harrington, KJ; Nutting, CM; et al. (2016-06-01) -
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller, LME; Holmes, M; Michael, JL; Scott, GB; West, EJ; et al. (BMJ PUBLISHING GROUP, 2019-07-01)BACKGROUND: The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer ... -
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings, VA; Scott, GB; Rose, AMS; Scott, KJ; Migneco, G; et al. (CELL PRESS, 2019-06-05)A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and ... -
Practice patterns for the radical treatment of nasopharyngeal cancer by head and neck oncologists in the United Kingdom.
Petkar, I; Bhide, S; Newbold, K; Harrington, K; Nutting, C (BRITISH INST RADIOLOGY, 2018-05-01)OBJECTIVE: Advances in radiation delivery, imaging techniques, and chemotherapy have significantly improved treatment options for non-metastatic nasopharyngeal cancers (NPC). However, their impact on the practice in the ... -
Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma.
Lee, JY; Garcia-Murillas, I; Cutts, RJ; De Castro, DG; Grove, L; et al. (SPRINGERNATURE, 2017-09-05)BACKGROUND: Following chemo-radiotherapy (CCRT) for human papilloma virus positive (HPV+) locally advanced head and neck cancer, patients frequently undergo unnecessary neck dissection (ND) and/or repeated biopsies for ... -
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett, E; Kottke, T; Thompson, J; Rajani, K; Zaidi, S; et al. (NATURE PUBLISHING GROUP, 2017-01-01)The anti-tumour effects associated with oncolytic virus therapy are mediated significantly through immune-mediated mechanisms, which depend both on the type of virus and the route of delivery. Here, we show that intra-tumoral ... -
Principal component analysis fosr fast and model-free denoising of multi b-value diffusion-weighted MR images.
Gurney-Champion, OJ; Collins, DJ; Wetscherek, A; Rata, M; Klaassen, R; et al. (IOP PUBLISHING LTD, 2019-04-09)Despite the utility of tumour characterisation using quantitative parameter maps from multi-b-value diffusion-weighted MRI (DWI), clinicians often prefer the use of the image with highest diffusion-weighting (b-value), for ... -
Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study.
Welsh, L; Panek, R; McQuaid, D; Dunlop, A; Schmidt, M; et al. (BIOMED CENTRAL LTD, 2015-05-15)BACKGROUND: Radical chemo-radiotherapy (CRT) is an effective organ-sparing treatment option for patients with locally advanced head and neck cancer (LAHNC). Despite advances in treatment for LAHNC, a significant minority ... -
Prostate-specific membrane antigen expression in melanoma metastases.
Snow, H; Hazell, S; Francis, N; Mohammed, K; O'Neill, S; et al. (WILEY, 2020-12-01)BACKGROUND: Prostate-specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga-PSMA-11) for prostate cancer staging. PSMA-PET/CT (positron emission tomography/computed tomography) ... -
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
Harrington, KJ; Soulières, D; Le Tourneau, C; Dinis, J; Licitra, LF; et al. (OXFORD UNIV PRESS INC, 2021-02-01)BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit. KEYNOTE-040 evaluated pembrolizumab vs standard ... -
Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.
Dillon, MT; Barker, HE; Pedersen, M; Hafsi, H; Bhide, SA; et al. (AMER ASSOC CANCER RESEARCH, 2017-01-01)AZD6738 is an orally active ATR inhibitor (ATRi) currently in phase I clinical trials. We found in vitro growth inhibitory activity of this ATRi in a panel of human cancer cell lines. We demonstrated radiosensitization by ...